Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) rose 11.3% on Friday . The company traded as high as $0.35 and last traded at $0.35. Approximately 100 shares changed hands during trading, a decline of 99% from the average daily volume of 8,177 shares. The stock had previously closed at $0.3145.
Defence Therapeutics Stock Up 11.3%
The company’s 50 day moving average is $0.35 and its 200 day moving average is $0.41.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Further Reading
- Five stocks we like better than Defence Therapeutics
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
